Bentzer Peter, Broman Marcus, Kander Thomas
Department of Anesthesia and Intensive Care Helsingborg Hospital, Helsingborgs lasarett, Charlotte Yhlens gata 10, 251 87, Helsingborg, Sweden.
Department of Clinical Sciences Lund, Lund University, Box 157, 221 00, Lund, Sweden.
Scand J Trauma Resusc Emerg Med. 2017 Jul 6;25(1):65. doi: 10.1186/s13049-017-0413-x.
Albumin may be beneficial in patients with septic shock but availability is limited and cost is high. The objective of the present study was to investigate if the use of dextran-70 in addition to albumin and crystalloids influences organ failure or mortality in patients with severe sepsis or septic shock.
Patients with severe sepsis or septic shock (n = 778) admitted to a university hospital intensive care unit (ICU) between 2007 and 2015 that received dextran-70 during resuscitation were propensity score matched to controls at a 1 to 1 ratio. Outcomes were highest acute kidney injury network (AKIN) score the first 10 days in the ICU, use of renal replacement therapy, days alive and free of organ support the first 28 days after admission to ICU, mortality and events of severe bleeding. Outcomes were assessed using paired hypothesis testing.
Propensity score matching resulted in two groups of patients with 245 patients in each group. The dextran group received a median volume of 1483 ml (interquartile range, 1000-2000 ml) of dextran-70 during the ICU stay. Highest AKIN score did not differ between the control- and dextran groups (1 (0-3) versus 2 (0-3), p = 0.06). Incidence of renal replacement therapy in the control- and dextran groups was similar (19% versus 22%, p = 0.42, absolute risk reduction -2.9% [95% CI: -9.9 to 4.2]). Days alive and free of renal replacement, vasopressors and mechanical ventilation did not differ between the control- and dextran groups. The 180-day mortality was 50.2% in the control group and 41.6% in the dextran group (p = 0.046, absolute risk reduction 8.6% [-0.2 to 17.4]). Fraction of patients experiencing a severe bleeding in the first 10 days in the ICU did not differ between the control and dextran groups (14% versus 18%, p = 0.21).
There is a paucity of high quality data regarding effects of dextran solutions on outcome in sepsis. In the present study, propensity score matching was used in attempt to reduce bias.
No evidence to support a detrimental effect of dextran-70 on mortality or on organ failures in patients with severe sepsis or septic shock could be detected.
白蛋白可能对感染性休克患者有益,但供应有限且成本高昂。本研究的目的是调查除白蛋白和晶体液外使用右旋糖酐70是否会影响严重脓毒症或感染性休克患者的器官功能衰竭或死亡率。
2007年至2015年期间入住大学医院重症监护病房(ICU)且在复苏期间接受右旋糖酐70治疗的严重脓毒症或感染性休克患者(n = 778)按倾向评分以1:1的比例与对照组进行匹配。观察指标为入住ICU的前10天内最高急性肾损伤网络(AKIN)评分、肾脏替代治疗的使用情况、入住ICU后第28天存活且无需器官支持的天数、死亡率以及严重出血事件。采用配对假设检验对观察指标进行评估。
倾向评分匹配后得到两组患者,每组各245例。右旋糖酐组在ICU住院期间接受的右旋糖酐70的中位剂量为1483 ml(四分位间距,1000 - 2000 ml)。对照组和右旋糖酐组的最高AKIN评分无差异(1(0 - 3)对2(0 - 3),p = 0.06)。对照组和右旋糖酐组肾脏替代治疗的发生率相似(19%对22%,p = 0.42,绝对风险降低 -2.9% [95% CI:-9.9至4.2])。对照组和右旋糖酐组存活且无需肾脏替代治疗、血管升压药和机械通气的天数无差异。对照组180天死亡率为50.2%,右旋糖酐组为41.6%(p = 0.046,绝对风险降低8.6% [-0.2至17.4])。对照组和右旋糖酐组在ICU的前10天内发生严重出血的患者比例无差异(14%对18%,p = 0.21)。
关于右旋糖酐溶液对脓毒症患者预后影响的高质量数据匮乏。在本研究中,采用倾向评分匹配以试图减少偏倚。
未发现有证据支持右旋糖酐70对严重脓毒症或感染性休克患者的死亡率或器官功能衰竭有不利影响。